R Squared’s Syndax Pharmaceuticals SNDX Stock Holding History

R Squared’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,940	Closed	-$25.6K	–	1322
2024 Q4	$25.6K	Buy	+1,940	New	+$33.2K	0.03%	770

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

R Squared's SNDX Position: Q1 2025 in Review

R Squared sold out of Syndax Pharmaceuticals (SNDX) in Q1 2025, closing a stake of 1,940 shares — an estimated $25.6K sold.

R Squared first reported a position in SNDX in Q4 2024 and held it in 1 quarter. The position peaked at $25.6K in Q4 2024. 218 funds tracked by Wall St. Rank hold SNDX as of Q1 2025.

R Squared reported no remaining Syndax Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,940 Syndax Pharmaceuticals shares in Q1 2025, an estimated $25.6K.
R Squared first reported a position in Syndax Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Syndax Pharmaceuticals position peaked at $25.6K in Q4 2024.
218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.